Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.
This report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Anti-CD279 (PD-1) Antibody pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Anti-CD279 (PD-1) Antibody R&D. The therapies under development are focused on novel approaches to treat/improve Anti-CD279 (PD-1) Antibody.
Anti-CD279 (PD-1) Antibody Emerging Drugs Chapters
This segment of the Anti-CD279 (PD-1) Antibody report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Anti-CD279 (PD-1) Antibody Emerging Drugs
IBI308: Innovent Biologics
IBI308/ Sintilimab is a fully human monoclonal antibody that blocking programmed death protein-1. Innovent holds the global intellectual property rights of IBI308. Currently IBI308 has been approved for marketing by the NMPA. Acting as an immune checkpoint inhibitor by targeting PD-1, IBI308 boosts the immune response against tumor cells and inhibits the immune escape of tumor cells. It is currently in Phase III for Acral Melanoma, Nasopharyngeal Neoplasms, and Gastric Cancer. It is being developed by Innovent Biologics.
Tislelizumab: BeiGene
Tislelizumab (BGB-A317) is a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to Fc?R on macrophages. In pre-clinical studies, binding to Fc?R on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers.
Anti-CD279 (PD-1) Antibody: Therapeutic Assessment
This segment of the report provides insights about the different Anti-CD279 (PD-1) Antibody drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Anti-CD279 (PD-1) Antibody
There are approx. 40+ key companies which are developing the therapies for Anti-CD279 (PD-1) Antibody. The companies which have their Anti-CD279 (PD-1) Antibody drug candidates in the most advanced stage, i.e. Phase III include, Innovent Biologics.
Phases
The report covers around 40+ products under different phases of clinical development like:
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of:
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Anti-CD279 (PD-1) Antibody pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
Molecule Type
Products have been categorized under various Molecule types such as:
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Pipeline Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anti-CD279 (PD-1) Antibody therapeutic drugs key players involved in developing key drugs.
Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anti-CD279 (PD-1) Antibody drugs.
Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Anti-CD279 (PD-1) Antibody drugs?
- How many Anti-CD279 (PD-1) Antibody drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Anti-CD279 (PD-1) Antibody?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Anti-CD279 (PD-1) Antibody therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Anti-CD279 (PD-1) Antibody and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- GlaxoSmithKline
- Innovent Biologics
- BeiGene
- Shanghai Junshi Biosciences
Key Products
- Dostarlimab
- Sintilimab
- Tislelizumab
- JS-003
- JS-201
- Toripalimab
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/3p5c15
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
